Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

7.510 +0.090 (+1.21%)

Streaming Delayed Price Updated: 1:23 PM EDT, Aug 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	114,187
Open	7.470
Bid (Size)	7.500 (200)
Ask (Size)	7.530 (300)
Prev. Close	7.420
Today's Range	7.392 - 7.760
52wk Range	3.530 - 9.620
Shares Outstanding	113,793,338
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 06, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

July 31, 2026

From Precision BioSciences, Inc.

Via Business Wire

Performance

YTD	+83.2%	+83.2%
1 Month	-18.8%	-18.8%
3 Month	+0.4%	+0.4%
6 Month	+110.4%	+110.4%
1 Year	+56.1%	+56.1%

More News

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

July 27, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

June 29, 2026

From Precision BioSciences, Inc.

Via Business Wire

These stocks are gapping in today's session ↗

June 08, 2026

Via Chartmill

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

May 27, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

May 21, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 14, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 05, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

April 30, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

April 29, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

April 28, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 24, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

April 22, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

April 15, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

March 12, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

March 11, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

March 10, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

March 09, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

March 09, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

March 02, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

February 18, 2026

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

February 11, 2026

From Precision BioSciences, Inc.

Via Business Wire

Frequently Asked Questions

Is Precision BioSciences, Inc. - Common Stock publicly traded?

Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.

What exchange does Precision BioSciences, Inc. - Common Stock trade on?

Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?

The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market

What is the current price of Precision BioSciences, Inc. - Common Stock?

The current price of Precision BioSciences, Inc. - Common Stock is 7.510

When was Precision BioSciences, Inc. - Common Stock last traded?

The last trade of Precision BioSciences, Inc. - Common Stock was at 08/07/26 01:23 PM ET

What is the market capitalization of Precision BioSciences, Inc. - Common Stock?

The market capitalization of Precision BioSciences, Inc. - Common Stock is 854.59M

How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?

Precision BioSciences, Inc. - Common Stock has 855M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.